fbpx

Acorda to Present Data for INBRIJA (levodopa inhalation powder) at 2nd Pan American Parkinsons Disease and Movement Disorders Congress

Acorda Therapeutics, Inc. (Nasdaq: ACOR) will present four encore
INBRIJA posters at the upcoming 2nd Pan American Parkinson’s
Disease and Movement Disorders Congress taking place June 22-24, 2018 in
Miami, Florida. INBRIJA is an investigational inhaled levodopa treatment
for symptoms of OFF periods in people with Parkinson’s disease taking a
carbidopa/levodopa regimen.

The INBRIJA posters will be presented on Saturday, June 23, 2018, as
part of Parkinson’s Disease: Clinical Trials, Pharmacology and Treatment
poster session from 1:00 PM – 2:30 PM. Posters will be available for
viewing from 9:00 AM to 5:00 PM. Details are as follows:

These data were previously presented at the American Academy of
Neurology Annual Meeting in April 2018, and included in a New Drug
Application for INBRIJA that was accepted for review by U.S. Food and
Drug Administration in February 2018. FDA has set a target PDUFA date of
October 5, 2018.

Acorda will also host a Corporate Therapeutics Symposium on Saturday,
June 23, 2018, from 12:15 PM – 1:15 PM ET. The symposium, titled Live
Well Do Tell: Taking the Next Step in the Management of Parkinson’s
Disease, will feature a panel of distinguished clinicians, including
Rajesh Pahwah, MD (panel chair), Connie Marras, MD, PhD and Cynthia
Comella, MD, PhD.

About Parkinson’s and OFF periodsParkinson’s is a
progressive neurodegenerative disorder resulting from the gradual loss
of certain neurons responsible for producing dopamine. Approximately one
million people in the U.S. and 1.2 million Europeans are diagnosed with
Parkinson’s; OFF periods are experienced by approximately 350,000 in the
U.S. and 420,000 in Europe. It causes a range of symptoms including
impaired movement, muscle stiffness and tremors. As Parkinson’s
progresses, people will experience OFF periods, which are characterized
by the re-emergence of Parkinson’s motor and non-motor symptoms. This
re-emergence can occur even when an individual’s treatment regimen has
been optimized.

About INBRIJA™ (levodopa inhalation powder) and ARCUS®INBRIJA
is a self-administered, orally inhaled levodopa (L-dopa) therapy in
development for the treatment of symptoms of OFF periods in people with
Parkinson’s disease taking a carbidopa/levodopa regimen.

INBRIJA utilizes Acorda’s investigational ARCUS® platform for inhaled
therapeutics. INBRIJA was designed to deliver a precise dose of a dry
powder formulation of L-dopa through the lung. Oral medication can be
associated with variable onset of action, as the medicine is absorbed
through the gastrointestinal (digestive) tract before reaching the
brain. Inhaled treatments enter the body through the lungs and reach the
brain, bypassing the digestive system.

The proprietary name INBRIJA has been conditionally accepted by the U.S.
Food and Drug Administration (FDA).

About Acorda TherapeuticsFounded in 1995, Acorda
Therapeutics is a biopharmaceutical company focused on developing
therapies that restore function and improve the lives of people with
neurological disorders. Acorda has a pipeline of novel neurological
therapies addressing a range of disorders, including Parkinson’s disease
and multiple sclerosis. Acorda markets two FDA-approved therapies,
including AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg.

Forward-Looking StatementThis press release includes
forward-looking statements. All statements, other than statements of
historical facts, regarding management’s expectations, beliefs, goals,
plans or prospects should be considered forward-looking. These
statements are subject to risks and uncertainties that could cause
actual results to differ materially, including: the ability to realize
the benefits anticipated from acquisitions, among other reasons because
acquired development programs are generally subject to all the risks
inherent in the drug development process and our knowledge of the risks
specifically relevant to acquired programs generally improves over time;
we may need to raise additional funds to finance our operations and may
not be able to do so on acceptable terms; our ability to successfully
market and sell Ampyra (dalfampridine) Extended Release Tablets, 10 mg
in the U.S., which will likely be materially adversely affected by the
March 2017 court decision in our litigation against filers of
Abbreviated New Drug Applications to market generic versions of Ampyra
in the U.S.; the risk of unfavorable results from future studies of
Inbrija (levodopa inhalation powder) or from our other research and
development programs, or any other acquired or in-licensed programs; we
may not be able to complete development of, obtain regulatory approval
for, or successfully market Inbrija or any other products under
development; risks associated with complex, regulated manufacturing
processes for pharmaceuticals, which could affect whether we have
sufficient commercial supply of Inbrija to meet market demand, if it
receives regulatory approval; third party payers (including governmental
agencies) may not reimburse for the use of Ampyra, Inbrija or our other
products at acceptable rates or at all and may impose restrictive prior
authorization requirements that limit or block prescriptions; the
occurrence of adverse safety events with our products; the outcome (by
judgment or settlement) and costs of legal, administrative or regulatory
proceedings, investigations or inspections, including, without
limitation, collective, representative or class action litigation;
competition; failure to protect our intellectual property, to defend
against the intellectual property claims of others or to obtain third
party intellectual property licenses needed for the commercialization of
our products; and failure to comply with regulatory requirements could
result in adverse action by regulatory agencies.

These and other risks are described in greater detail in our filings
with the Securities and Exchange Commission. We may not actually achieve
the goals or plans described in our forward-looking statements, and
investors should not place undue reliance on these statements.
Forward-looking statements made in this press release are made only as
of the date hereof, and we disclaim any intent or obligation to update
any forward-looking statements as a result of developments occurring
after the date of this press release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180618005022/en/